Tempus ECG-AF vs TeraRecon Cardiovascular.Calcification.CT
AI Verdict
Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your primary goal is to proactively identify older patients (65+) at increased risk of developing new-onset atrial fibrillation within the next year, utilizing readily available 12-lead ECG data. This tool is ideal for early risk stratification and guiding follow-up in a population without pre-existing AF or cardiac devices, aiming to prevent future cardiac events.
View Tempus ECG-AF →Choose TeraRecon Cardiovascular.Calcification.CT if…
Choose TeraRecon Cardiovascular.Calcification.CT if you require detailed, automated analysis of coronary artery calcification from CT images to quantify atherosclerotic burden. This tool is best suited for precise calcium scoring (Agatston, volume, mass) and comprehensive vessel analysis, supporting the evaluation of existing coronary artery disease and pre-operative planning.
View TeraRecon Cardiovascular.Calcification.CT →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-AF | TeraRecon Cardiovascular.Calcification.CT |
|---|---|---|
| Pricing | Contact vendor | Unknown |
| Deployment | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. | Cloud-enabled imaging platform. |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Yes AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
TeraRecon Cardiovascular.Calcification.CTTool B's 'zero-click centerline creation' and availability as a containerized application or SaaS within the Eureka Clinical AI platform suggest a highly automated and flexible user experience. While Tool A integrates with existing ECG systems, Tool B's deployment options and specific automation features point to potentially greater ease of use and integration into diverse enterprise environments.
Clinical Value
TeraRecon Cardiovascular.Calcification.CTTool B offers a comprehensive suite of advanced diagnostic and planning tools for cardiovascular assessment from CT images, including detailed calcification scoring, vessel analysis, and cardiac structure segmentation. While Tool A provides valuable early AF risk prediction from ECGs, Tool B's broader feature set addresses a wider range of clinical needs for diagnosis, risk stratification, and procedural planning.
Pricing & Value
Tempus ECG-AFTool A has a clear and established CMS reimbursement pathway with a specified Medicare rate, offering a direct and tangible financial benefit to healthcare providers. While Tool B offers predictable subscription costs, the explicit reimbursement for Tool A provides a more immediate and measurable return on investment for adopting institutions.
Enterprise Readiness
TieBoth tools are FDA-cleared, HIPAA compliant, and offer Business Associate Agreements, indicating a high level of readiness for enterprise deployment. Their respective integration and deployment models are designed to fit within existing healthcare IT infrastructures, making them equally prepared for organizational adoption.
Innovation
Tempus ECG-AFTool A demonstrates significant innovation by leveraging a standard, inexpensive 12-lead ECG to predict the risk of new-onset Atrial Fibrillation within 12 months. This predictive capability from a readily available diagnostic tool represents a novel approach to early intervention and preventative cardiology. While Tool B offers advanced automation in CT analysis, Tool A's application of AI to a common test for predictive risk is particularly innovative.
Support & Docs
TeraRecon Cardiovascular.Calcification.CTTeraRecon (Tool B) provides detailed information on customer support channels, including multiple phone numbers (with emergency options) and email, along with clear access to electronic user manuals online and within the software, with an option for hard copies. Tempus (Tool A) offers email and general contact information, but less specific detail regarding documentation access for its ECG-AF product.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-AF | TeraRecon Cardiovascular.Calcification.CT |
|---|---|---|
| Tool Name | Tempus ECG-AF | TeraRecon Cardiovascular.Calcification.CT |
| Company | Tempus AI, Inc. | TeraRecon |
| Description | FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. | AI-powered software as a medical device (SaMD) that analyzes CT images to automatically detect and measure calcifications in the coronary arteries, providing a mask for calcium scoring systems. |
| Primary Data Input | 12-lead ECG recordings | CT images |
| Key Functionality | Detects signs associated with new onset Atrial Fibrillation (AF) within 12 months for patients 65 years or older. | Automatic 3D segmentation of calcified plaques in coronary arteries and outputs mask for calcium scoring systems. |
| Target Patient Population/Use Case | Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery, at increased risk of developing AF/flutter. | Not specified (focuses on calcification detection for calcium scoring systems). |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-AF and TeraRecon Cardiovascular.Calcification.CT.